Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Boehringer Ingelheim Launches New SGLT-2 Inhibitor Esgliteo

Tuesday, July 18, 2023

Boehringer Ingelheim has launched Esgliteo (empagliflozin/linagliptin), a compound therapy of the SGLT-2 inhibitor Jardiance (empagliflozin) and the DPP-4 inhibitor Trajenta (linagliptin).

Esgliteo is its smaller tablet size, measuring approximately 8.1 millimetres. This size is intended to enhance convenience for patients who struggle with swallowing larger pills. Additionally, Esgliteo offers two dosage options to cater to patients in need of additional glycaemic control: 10 mg of empagliflozin combined with 5 mg of linagliptin, or 25 mg of empagliflozin with 5 mg of linagliptin.

Esgliteo brings several benefits as a combination therapy. Firstly, it delivers a superior glucose-lowering effect compared to either medication used alone. In the EMPA-REG OUTCOME study, empagliflozin, the SGLT-2 inhibitor component, demonstrated a significant cardiovascular benefit by reducing the risk of major cardiovascular events (cardiovascular-related death, nonfatal myocardial infarction, or nonfatal stroke) by 14% compared to a placebo.

Esgliteo harnesses the complementary mechanisms of SGLT-2 and DPP-4 inhibitors to achieve enhanced glucose control. In a phase 3 study, Esgliteo exhibited improved glycemic control at week 24 when compared to using empagliflozin or linagliptin alone as monotherapies.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024